ANIP - ANI Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$124.00
DETAILS
HIGH:
$124.00
LOW:
$124.00
MEDIAN:
$124.00
CONSENSUS:
$124.00
UPSIDE:
49.90%
Institutional Holders (13F)
| GURU | SHARES | VALUE | WEIGHT % | SHARES CHG | ACTION |
|---|---|---|---|---|---|
| Cooperman | 213,433 | $16.4M | 0.0% | -40,103 | DECREASED |
| Greenblatt | 24,095 | $1.9M | 0.0% | -8,747 | DECREASED |
| Laffont | 12,918 | $993,394 | 0.1% | +2,331 | INCREASED |
| Wood | 0 | $0 | -- | -121,211 | SOLD |
Insider Trading
| DATE | INSIDER | TITLE | TYPE | SHARES | PRICE | VALUE |
|---|---|---|---|---|---|---|
| 2026-05-11 | Walsh Patrick D | director | SELL | 3,973 | $80.75 | $321K |
| 2026-05-13 | Walsh Patrick D | director | SELL | 10,000 | $80.63 | $806K |
| 2026-05-12 | Gutwerg Ori | officer: SVP, GENERICS | SELL | 2,772 | $79.50 | $220K |
| 2026-05-12 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | SELL | 459 | $79.21 | $36K |
| 2026-05-11 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | SELL | 55,000 | $77.57 | $4.3M |
| 2026-05-13 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $78.16 | $39K |
| 2026-04-13 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $77.95 | $39K |
| 2026-03-13 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | SELL | 500 | $72.62 | $36K |
| 2026-03-11 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | SELL | 4,772 | $74.91 | $357K |
| 2026-03-13 | Mutz Christopher | officer: HEAD OF RARE DISEASE | SELL | 3,162 | $71.64 | $227K |
| 2026-03-06 | Mutz Christopher | officer: HEAD OF RARE DISEASE | SELL | 2,121 | $74.22 | $157K |
| 2026-03-07 | Mutz Christopher | officer: HEAD OF RARE DISEASE | F-InKind | 3,314 | $74.04 | $245K |
| 2026-03-09 | Mutz Christopher | officer: HEAD OF RARE DISEASE | SELL | 3,602 | $74.18 | $267K |
| 2026-03-07 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | F-InKind | 17,060 | $74.04 | $1.3M |
| 2026-03-07 | Gutwerg Ori | officer: SVP, GENERICS | F-InKind | 3,314 | $74.04 | $245K |
| 2026-03-06 | Davis Krista | officer: SVP, CHIEF HR OFFICER | SELL | 1,485 | $75.00 | $111K |
| 2026-03-09 | Davis Krista | officer: SVP, CHIEF HR OFFICER | SELL | 5,087 | $74.13 | $377K |
| 2026-03-07 | CAREY STEPHEN P. | officer: SVP & CFO | F-InKind | 5,150 | $74.04 | $381K |
| 2026-03-05 | CAREY STEPHEN P. | officer: SVP & CFO | SELL | 4,000 | $75.56 | $302K |
| 2026-03-05 | CAREY STEPHEN P. | officer: SVP & CFO | M-Exempt | 3,312 | $49.51 | $164K |
| 2026-03-05 | CAREY STEPHEN P. | officer: SVP & CFO | SELL | 3,312 | $75.42 | $250K |
| 2026-03-02 | Mutz Christopher | officer: HEAD OF RARE DISEASE | SELL | 417 | $74.00 | $31K |
| 2026-03-03 | Gutwerg Ori | officer: SVP, GENERICS | SELL | 2,060 | $76.50 | $158K |
| 2026-03-03 | Walsh Patrick D | director | SELL | 6,000 | $74.23 | $445K |
| 2026-02-28 | Gutwerg Ori | officer: SVP, GENERICS | F-InKind | 2,221 | $73.90 | $164K |